trding wrote:
That comment may have been tongue-in-cheek, but I agree with you trding. And it is important to note that the audience laughed at Rodney Dangerfield when he claimed he "got no respect" because of the character he portrayed.
Earlier today, MoonShot303 wrote:
And yet Redchip is not even the worst offender in this equation (although I think the conference call on 2/20/2020 was a spectacular failure). Think for a moment about what yesterday's Wall Street Reporter presentation looks like to a mainstream investor who does not deal with OTC stocks, or the dozens of web articles that appear on disreputable pump-and-dump websites, or the flurry of press releases that contain hyperbolic language (or regurgitate old information or fix previously supplied "inaccurate" information), or the many, many Proactive videos.
Look, I really appreciate the amount of transparency and information that NP provides -- it's probably way more than he should be sharing. However, as a new investor in CYDY, and as many of you know, I spent weeks trying to figure out exactly what was going on here. Like many potential investors that we all hope will come onboard, I don't live in an OTC world, and the companies I follow are operating on a completely different level (read: professional).
Let's face it, we all believe in this drug -- otherwise we wouldn't be here. We all want this drug to save lives and improve outcomes for people suffering all over the world. And, we all want to profit from our support of the company. However, like Rodney Dangerfield, we "get no respect" largely because of the way the company is portrayed.
Like everyone else, I've had plenty of time to run the playbook on how this current chapter unfolds. And interestingly, there are a number of events, each having largely binary outcomes, that are all clustered within the exact same time frame. I think we can agree that the big ticket events are as follows:
1. COVID Efficacy: 2-3 Weeks
2. BLA Filing: 2-3 Weeks
3. BTD: 2-3 Weeks (4/6/2020)
4. FINANCING: 1-6 Weeks
I agree with trding that "if those two patients recover, leronlimab would get some national exposure." I think if we are lucky enough to help those patients, we will save lives (which would be absolutely fabulous) -- but likely not profit directly from it.
I can't imagine that any company that develops a therapeutic or vaccine for this virus will be able to sell it for a price that is much above cost of goods (COGS). However, COVID Efficacy would provide national exposure, add validation and legitimacy, and begin to take the "stink" off of the way the company has been portrayed in, and perceived by, the market.
If we are lucky enough to have one or two of the other events listed above happen at the same time as COVID Efficacy, I imagine we'd see some significant stock price appreciation.
Alternatively, if we fail to succeed with COVID Efficacy, and two or three of the other events listed above happen at around the same time, I can also envision the some significant stock appreciation.
Looking further down the road, and as NP kind of referenced in the conference call on 3/5/2020, I could see BP interest being entertained if events 2, 3, and 4 happen -- and are followed-up by positive results in the Basket Trial and/or GvHD and/or NASH and/or another BTD from the FDA.
As always, IMO.
Quote:I would imagine if those two patients recover, leronlimab would get some national exposure, but who knows for certain cydy is the Rodney Dangerfield of biotech.
That comment may have been tongue-in-cheek, but I agree with you trding. And it is important to note that the audience laughed at Rodney Dangerfield when he claimed he "got no respect" because of the character he portrayed.
Earlier today, MoonShot303 wrote:
Quote:I'm in a trading chatroom that usually has approximately 500 active traders on any given day. CYDY is looked at as an OTC pump in that chatroom, and Redchip is looked at as a notorious OTC pump promoter.
And yet Redchip is not even the worst offender in this equation (although I think the conference call on 2/20/2020 was a spectacular failure). Think for a moment about what yesterday's Wall Street Reporter presentation looks like to a mainstream investor who does not deal with OTC stocks, or the dozens of web articles that appear on disreputable pump-and-dump websites, or the flurry of press releases that contain hyperbolic language (or regurgitate old information or fix previously supplied "inaccurate" information), or the many, many Proactive videos.
Look, I really appreciate the amount of transparency and information that NP provides -- it's probably way more than he should be sharing. However, as a new investor in CYDY, and as many of you know, I spent weeks trying to figure out exactly what was going on here. Like many potential investors that we all hope will come onboard, I don't live in an OTC world, and the companies I follow are operating on a completely different level (read: professional).
Let's face it, we all believe in this drug -- otherwise we wouldn't be here. We all want this drug to save lives and improve outcomes for people suffering all over the world. And, we all want to profit from our support of the company. However, like Rodney Dangerfield, we "get no respect" largely because of the way the company is portrayed.
Like everyone else, I've had plenty of time to run the playbook on how this current chapter unfolds. And interestingly, there are a number of events, each having largely binary outcomes, that are all clustered within the exact same time frame. I think we can agree that the big ticket events are as follows:
1. COVID Efficacy: 2-3 Weeks
2. BLA Filing: 2-3 Weeks
3. BTD: 2-3 Weeks (4/6/2020)
4. FINANCING: 1-6 Weeks
I agree with trding that "if those two patients recover, leronlimab would get some national exposure." I think if we are lucky enough to help those patients, we will save lives (which would be absolutely fabulous) -- but likely not profit directly from it.
I can't imagine that any company that develops a therapeutic or vaccine for this virus will be able to sell it for a price that is much above cost of goods (COGS). However, COVID Efficacy would provide national exposure, add validation and legitimacy, and begin to take the "stink" off of the way the company has been portrayed in, and perceived by, the market.
If we are lucky enough to have one or two of the other events listed above happen at the same time as COVID Efficacy, I imagine we'd see some significant stock price appreciation.
Alternatively, if we fail to succeed with COVID Efficacy, and two or three of the other events listed above happen at around the same time, I can also envision the some significant stock appreciation.
Looking further down the road, and as NP kind of referenced in the conference call on 3/5/2020, I could see BP interest being entertained if events 2, 3, and 4 happen -- and are followed-up by positive results in the Basket Trial and/or GvHD and/or NASH and/or another BTD from the FDA.
As always, IMO.
8
